Efficacy and safety of basiliximab in pediatric renal transplantation.
García-Meseguer
C
C
Section of Pediatric Nephrology, Children's Hospital La Paz, Madrid, Spain.
Roldán
M
M
Melgosa
M
M
Alonso
A
A
Peña
A
A
Espìnosa
L
L
Navarro
M
M
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D002648:Child; D002675:Child, Preschool; D003404:Creatinine / Q000378:metabolism; D016572:Cyclosporine / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000517:prevention & control; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000627:therapeutic use; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins; D012449:Safety; D016559:Tacrolimus / Q000627:therapeutic use; D013997:Time Factors
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab; D003404:Creatinine; D009173:Mycophenolic Acid; D015774:Ganciclovir; D011241:Prednisone; D016559:Tacrolimus